Several CD19 point mutations have been reported in patients with diffuse large B cell lymphoma (DLBCL) and B-acute lymphoblastic leukemia (B-ALL) who showed resistance to CART19 cell therapy. Here, CD19 is linked to acute lymphoblastic leukemia.